期刊
EXPERT OPINION ON BIOLOGICAL THERAPY
卷 8, 期 2, 页码 235-247出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712598.8.2.235
关键词
haemodialysis; HBV-AS04 vaccine; hepatitis B; immunisation; immunogenicity; novel adjuvant; reactogenicity
Background: High susceptibility to infections including the hepatitis B virus (HBV) causes increased morbidity and mortality in patients with end stage renal disease. HBV vaccination is recommended for all patients undergoing dialysis; however, antibody response is much lower than in healthy individuals. Objective: This review discusses the clinical experience with HBV vaccine with a novel adjuvant system among dialysed patients. Method: A new adjuvanted HBV vaccine (Fendrix (TM), GlaxoSmithKline Biologicals, Rixensart, Belgium) contains as active substance 20 mu g recombinant hepatitis B surface antigen produced in Saccharomyces cerevisiae and the novel adjuvant system composed of aluminum salt and 3-O-desacyl-4'-monophosphoryl lipid A (AS04). Conclusion: HBV-AS04 vaccine has a good safety profile with clinically acceptable reactions similar to standard HBV vaccines and has elicited earlier antibody response and higher antibody titres in pre and haemodialysis patients as compared with four double doses of standard HBV vaccine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据